Guardant360® ctDNA liquid biopsy for treatment selection of patients with NSCLC

29 May 2020
Guardant360® ctDNA liquid biopsy for treatment selection of patients with NSCLC
Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.

Resources

SG-GDH-001

SG-GDH-001

SG-GDH-001

SG-GDH-001